Press Release:
CDEX to Attend Health Connect Partners 2011 Fall Hospital Pharmacy Conference
ValiMed G4 Medication Validation System Demonstrated at Event
tweet0EmailPrintCompanies:CDEX INC CL A Related Quotes
Symbol Price Change
CEXI.OB 0.0380 0.00
{"s" : "cexi.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: CDEX Inc. On Tuesday September 27, 2011, 9:00 am
TUCSON, AZ--(Marketwire -09/27/11)- CDEX Inc. (OTC.BB: CEXI.OB - News), a leading developer of chemical detection products, using patented technologies for use in healthcare, safety and security markets, will demonstrate the capabilities of the ValiMed™ G4 drug validation system at the 2011 Health Connect Partners Fall Hospital Pharmacy Conference. The conference is taking place September 26-28, 2011 at the Arizona Biltmore in Phoenix, Ariz.
The Hospital Pharmacy Conference connects healthcare providers and suppliers through a selection of educational meetings and conferences. The conference is known for its large scale Reverse Expo with hospital pharmacy-hosted booths. Suppliers have a unique opportunity to gain a deeper understanding of their clients' needs and preferences.
Senior members of the CDEX team will be attending the semi-annual event which connects healthcare industry leaders and provides education on the current state of hospital pharmacy business and legislation.
"Attending the Health Connect Partners conference is a vital part of our continued efforts to market our new ValiMed G4 directly to the key decision makers in the healthcare pharmacy system. The conference provides an optimum environment to build and enhance relationships with top hospital and health system pharmacy executives from across the US. The event is a great platform to launch our VG4 and further build our pipeline of interested agencies. We expect to deliver our first VG4 unit ahead of schedule," stated Jeff Brumfield, chairman and chief executive officer of CDEX.
The ValiMed G4 drug validation system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate with electronic medical record (EMR) platforms.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
Contact:
Company contact: Jeff Brumfield (520) 745-5172 Email Contact Sales contact:John McConnell(615) 218-7993Email Contact
AI
